Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients (ReBIC-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02689180|
Recruitment Status : Unknown
Verified February 2016 by Hospital de Clinicas de Porto Alegre.
Recruitment status was: Recruiting
First Posted : February 23, 2016
Last Update Posted : February 23, 2016
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure||Drug: Placebo Drug: Furosemide||Phase 3|
Diuretics play a central role in HF treatment, particularly during episodes of acute decompensation. Furosemide is the prototype of loop diuretics, acting through the inhibition of the Na+K+2Cl- pump at the thick ascending limb of the Henle loop. According to international registries, almost all patients receive a loop diuretic during a hospital stay for acute decompensated HF and the majority are discharged taking a "maintenance dose". Despite the undeniable beneficial hemodynamic effects of improvement of peripheral and central congestion, the net clinical effect of the chronic use of diuretics on HF prognosis is controversial.
Observational studies suggest that use of high doses of diuretics might be related to unfavorable clinical consequences. Undesirable side effects of loop diuretics are not trivial and involve activation of the renin-angiotensin-aldosterone system, elevation of norepinephrine levels, increases in heart rate, detrimental effects on renal function and several electrolyte disturbances.
Few prospective clinical studies, however, directly evaluated the clinical risks and benefits of diuretics. Most of these studies were under-powered, performed more than 2 decades ago, before modern HF therapy with current drugs and devices was completely implemented.
Current clinical guidelines are unanimous to recommend use of diuretics in HF patients with clinical signs and symptoms of congestion, but reinforce the lack of solid clinical scientific evidence for its use, and the potential risks that might be involved. The European Society of Cardiology proposes the administration of the lowest dose necessary to achieve euvolemia, avoiding the unnecessary delay in the use of drugs that modify the natural history of the disease.
Based on these uncertainties about diuretic use in HF, the ReBIC-1 trial was designed to evaluate the potential clinical risks and benefits of withdrawing furosemide use in stable, apparently euvolemic, chronic HF outpatients in a multicentric double-blinded randomized clinical trial.
ReBIC is a Brazilian research network created to develop clinical studies in heart failure and composed predominantly by university tertiary care hospitals. ReBIC and the ReBIC-1 trial were sponsored by the Brazilian National Council for Scientific and Technological Development (CNPq, Brazil), a public governmental institution. Data collection, management, and analysis were performed at the network's data coordinating center at Hospital de Clínicas de Porto Alegre. All the authors reviewed and approved the manuscript and assume full responsibility for the accuracy and completeness of the data and for the fidelity of this report of the study protocol.
ReBIC-1 is a randomized, double-blind, parallel group, placebo-controlled, two-arm trial comparing the short-term efficacy and safety of discontinuation of furosemide in apparently euvolemic outpatients with chronic stable HF and reduced left ventricular ejection fraction (HF-REF).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||230 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients With Left Ventricular Dysfunction - the Brazilian Research Network on Heart Failure|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||July 2017|
Placebo Comparator: Withdraw of furosemide
Withdraw of of 40 or 80 mg of furosemide per day
Replacement of furosemide by placebo
Active Comparator: Maintenance of furosemide
Maintenance of 40 or 80 mg of furosemide per day
Maintenance of furosemide on usual doses
- Feasibility of furosemide withdraw - proportion of patients maintained without diuretic during follow-up [ Time Frame: 90 days ]Proportion of patients maintained without diuretic during follow-up
- Safety of furosemide withdraw - dyspnea score variation assessed by a visual analog scale [ Time Frame: 90 days ]Dyspnea score variation assessed by a visual analog scale after randomization
- Variation of plasmatic levels of natriuretic peptides [ Time Frame: Baseline and 90 days ]Levels of the N-terminal brain natriuretic peptide (NT pro-BNP)
- Variation in meters walked assessed by the 6 minute walking test [ Time Frame: Baseline and 90 days ]
- Variation in renal function [ Time Frame: Baseline, 15, 45 and 90 days ]Change in glomerular filtration rate ( ml/min /1.73 m²) estimated by the Modification of Diet in Renal Disease equation ( MDRD)
- Variation on the Clinical Congestion Score [ Time Frame: Baseline, 15, 45 and 90 days ]Clinical congestion score assessed by clinical history and physical examination (score from 1 to 22 point)
- Clinical composite endpoints [ Time Frame: 90 days ]Hospital admissions, emergency room visits and death within 90 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02689180
|Contact: Luis Eduardo Rohde, PHDemail@example.com|
|Contact: Priscila Raupp da Rosa, MDfirstname.lastname@example.org|
|Cardiovascular Division, Hospital de Clínicas de Porto Alegre||Recruiting|
|Porto Alegre, RS, Brazil, 90035-903|
|Contact: Luis Eduardo Rohde, PHD 55513359 8843 email@example.com|
|Contact: Priscila Raupp da Rosa, MD 555199127137 firstname.lastname@example.org|
|Sub-Investigator: Priscila Raupp da Rosa, MD|
|Principal Investigator: Luis E. Rohde, MD|
|Principal Investigator: Andreia Biolo, MD|
|Study Chair:||Luis Eduardo Rohde, PHD||Hospital de Clínicas de Porto Alegre|